SpringWorks Therapeutics price target raised to $52 from $47 at Goldman Sachs

Goldman Sachs raised the firm’s price target on SpringWorks Therapeutics to $52 from $47 and keeps a Buy rating on the shares. The analyst cites the announcement of an FDA approval of Ogsiveo, or nirogacestat, in desmoid tumors, with a label that was “largely in-line” with the firm’s bull case expectations. The label also did not contain a black box warning or REMS program for ovarian dysfunction, even though the disorder is noted as a warning/precaution, the firm tells investors in a research note.